6 results about "Synapsis" patented technology

A peptide or peptide analogue (P1) containing at least 5 N-terminal proteinogenic or non-proteinogenic amino acid residues of the IEX1X2V sequence, wherein: a. X1 from tyrosine (Y), serine (S) b. X2 was selected from alanine (A), aspartic acid (D).

Described herein are compositions and techniques related to generation and therapeutic application of artificial synapses. Artificial synapses are engineered extracellular vesicles, including exosomes, which incorporate sticky binders on their surface to anchor signaling domains against biological targets, such as receptors. These engineered additives can be organized in genetic vector constructs, expressed in mammalian cells, wherein the sticky binders attach to extracellular vesicles such as exosomes, thereby presenting their joined signaling domains which are rapidly taken up by recipient cells. Artificial synapses adopt the hallmark biophysical and biochemical features of extracellular vesicles, allowing for rapid deployment and scale-up. Importantly, this strategy can allow for kinetically favorable signal generation and signal propagation. This includes, for example, increasing density of agonist presentation to support receptor clustering—an onerous barrier for traditional receptor targeting strategies.

The present invention discloses a method and a kit for detecting botulinum toxin activity or synaptosome-associated proteins. The method comprises the step of contacting a sample to be tested with an antibody or an antigen-binding fragment thereof, wherein the antibody or the antigen-binding fragment thereof targets the synaptosome-associated protein or its cleavage fragment. The present invention obtains a humanized single-chain antibody against synaptosome-associated proteins from an antibody library, thereby ensuring that the antibodies are fully humanized, constructs a eukaryotic expression vector with the aid of genetic engineering technology, and expresses the antibodies in eukaryotic cells. In addition, the present invention converts the obtained fully humanized single-chain antibody into a specific fully humanized complete antibody, which is then separated and purified, and its biological properties such as specificity and affinity are evaluated, thereby establishing a method for detecting botulinum toxin activity and a method for detecting synaptosome-associated proteins. In addition, the affinity of the anti-synaptosome-associated protein antibody of the present invention is higher than that of the commercially available rabbit synaptosome-associated protein polyclonal antibody.

The invention discloses application of a substance taking ANGPTL4 protein or a coding gene thereof as a target spot in preparation of a product for treating cerebellar ataxia. The invention belongs to the technical field of biology, and particularly relates to application of a substance taking ANGPTL4 or a coding gene thereof as a target spot in preparation of a product for treating cerebellar ataxia. The invention provides an application of a substance for reducing ANGPTL4 gene expression, a substance for reducing ANGPTL4 protein activity or a substance for reducing ANGPTL4 protein content in preparation of a product for treating or / and preventing or / and delaying cerebellar ataxia and an application of a product for reducing formation of inhibitory synapses.

Provided herein are novel signal peptides that direct encoded proteins to synapses, recombinant polypeptides comprising the signal peptides, nucleic acid molecules encoding the recombinant polypeptides, pharmaceutical compositions comprising the nucleic acid molecules, and methods of use thereof.

The invention discloses a method for estimating radiation biological dose by using acrocentric chromosome synapsis, comprising: 1) irradiating a sample, comprising irradiating a human peripheral blood sample in a container by using radiation; 2) culturing the sample, comprising culturing the irradiated sample, comprising adding a culture solution and culturing in a 37°C incubator for 48-56 hours; 3) harvesting a cell suspension, comprising performing a harvesting operation after culturing to obtain a cell suspension; 4) dropping a slide, comprising dropping the cell suspension on a precooled glass slide and burning the suspension for 1-2 seconds with an alcohol lamp; 5) staining, staining the glass slide with a Giemsa staining solution; 6) reading and counting, comprising counting the incidence of chromosome synapsis by using a microscope; and 7) fitting a dose-effect curve based on the correlation between the incidence of chromosome synapsis and the irradiation dose, and estimating the radiation dose by using the dose-effect curve.